Results Of An Interim Safety Analysis Of A Phase 2 Study Of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, And Dexamethasone (Cybord) In Previously Untreated And Relapsed Patients (Pts) With Multiple Myeloma (Mm)
BLOOD（2017）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要